Io­vance's TIL ther­a­py plus Keytru­da show durable treat­ment ef­fect in melanoma, but ac­cess re­mains a ques­tion

CHICA­GO — Io­vance Bio­ther­a­peu­tics said Fri­day that adding its melanoma cell ther­a­py on top of an im­munother­a­py — the cur­rent go-to for ad­vanced skin can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.